Flash FinanceUS
Market open S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Viridian Therapeutics, Inc.\DE (VRDN)

Viridian Therapeutics wins FDA approval for Lumvoa for thyroid eye disease

Positive Impact 4 of 5 product/contract Written later

The FDA approved Viridian Therapeutics' Lumvoa (veligrotug-vvze) for thyroid eye disease regardless of disease activity or duration, and the company plans to launch it immediately. The approval is Viridian's first FDA-approved product and first commercial product, a milestone that moves the company from development toward sales.

Key points

  • FDA approval announced June 26, 2026; Lumvoa is the first TED treatment with labeling covering both active and chronic TED
  • Launch planned immediately; physicians can prescribe Lumvoa tomorrow, per the press release
  • Lumvoa is given as five intravenous infusions over 12 weeks; infusion reactions reported in about 9% of patients
  • Conference call and webcast scheduled Monday, June 29, 2026 at 8:00 a.m. ET

The filing

CompanyViridian Therapeutics, Inc.\DE (VRDN)
Form8-K, current report
Filed with the SECJun 26, 2026, 6:18 PM ET
Accession number0001193125-26-286273

Items reported: 7.01 Regulation FD Disclosure8.01 Other Events

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 8:38 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on June 26, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.